Evidence map›Paper›PMID 37284233›Full record

ReviewTrends in cancer2023

Endogenous and imposed determinants of apoptotic vulnerabilities in cancer.

Kristopher A Sarosiek, Kris C Wood

Open access · greenAbstract readReview
In one paragraph

Review in Trends in cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Kristopher A SarosiekMolecular and Integrative Physiological Sciences Program, Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Kris C WoodDepartment of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
Duke University · US

Funding

Translational Research Support CoreP30ES000002 · NIEHS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI JAIME ELIZABETH HART · 1985 to 2026
$44.6M
Screening for Cys-Reactive Ligands to Target PAX3-FOXO1U54CA231630 · NCI · DUKE UNIVERSITY · PI COUNTER, CHRISTOPHER M, LINARDIC, CORINNE MARY · 2019 to 2023
$6.5M
Developmental regulation of apoptosis as a modifiable driver of radiotherapy-induced neurocognitive impairment in pediatric patientsR37CA248565 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Kristopher Andrew Sarosiek · 2020 to 2026
$2.6M
Lineage-specific signaling and targeting of PI3K gamma in myeloid malignanciesR01CA266389 · NCI · DUKE UNIVERSITY · PI Kris C. Wood · 2022 to 2026
$2.0M
Selectively targeting apoptosis in PIK3CA mutant colorectal cancersR01CA207083 · NCI · DUKE UNIVERSITY · PI WOOD, KRIS C. · 2016 to 2020
$1.8M
Mechanism-based targeting of unique survival signaling in residual tumorsR01CA263593 · NCI · DUKE UNIVERSITY · PI Kris C. Wood · 2022 to 2026
$1.7M
Identifying targetable apoptotic vulnerabilities for the treatment of AL amyloidosisR01DK125263 · NIDDK · HARVARD SCHOOL OF PUBLIC HEALTH · PI SAROSIEK, KRISTOPHER ANDREW · 2020 to 2023
$1.4M
NCI NIH HHS R01 CA207083NCI NIH HHS R01 CA263593NCI NIH HHS R01 CA266389NCI NIH HHS R37 CA248565NCI NIH HHS U54 CA231630NIDDK NIH HHS R01 DK125263NIEHS NIH HHS P30 ES000002
6 · The paper itself

Abstract

The intrinsic apoptosis pathway is controlled by the BCL-2 family of proteins. Although the pro-survival members of this family can help cancer cells evade apoptosis, they may also produce apoptotic vulnerabilities that can potentially be exploited therapeutically. Apoptotic vulnerabilities can be driven by endogenous factors including altered genetics, signaling, metabolism, structure and lineage or differentiation state as well as imposed factors, the most prominent being exposure to anti-cancer agents. The recent development of BH3 mimetics that inhibit pro-survival BCL-2 family proteins has allowed these apoptotic vulnerabilities to be targeted with demonstrable clinical success. Here, we review the key concepts that are vital for understanding, uncovering, and exploiting apoptotic vulnerabilities in cancer for the potential improvement of patient outcomes.

Indexed as

Antineoplastic AgentsNeoplasmsApoptosisApoptosis Regulatory ProteinsHumansProto-Oncogene Proteins c-bcl-2Antineoplastic AgentsApoptosis Regulatory ProteinsProto-Oncogene Proteins c-bcl-2apoptosisBCL-2 familyBH3 mimeticscancer therapeuticschemotherapymitochondriatargeted therapy

Identifiers

PMID37284233
PMCPMC10241480
OpenAlexW4307927395

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.